Phase 1 open-label study assessing the pharmacokinetics and safety of TV-46000, a novel long-acting subcutaneous injectable formulation of risperidoneA. Merenlender Wagner, A. Elgart,I. Perlstein, M. Lamson, R. Tiver, A. Kalmanczhelyi, O. Spiegelstein, A. Mackellar, E. HararyEuropean Neuropsychopharmacology（2021）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
